Molecular Medicine, The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia.
Department of Surgery, The University of Melbourne, Parkville, VIC, Australia.
Adv Exp Med Biol. 2019;1139:1-21. doi: 10.1007/978-3-030-14366-4_1.
Glioblastoma is a primary tumor of the brain with a poor prognosis. Pathological examination shows that this disease is characterized by intra-tumor morphological heterogeneity, while numerous and ongoing genomic analysis reveals multiple layers of heterogeneity. Intra-tumor and patient-to-patient heterogeneity is underpinned by cellular, genetic, and molecular heterogeneity, which is thought to be key determinants of time to tumor recurrence and resistance to therapy. The key cell type believed to contribute to the establishment and ongoing evolution of tumor heterogeneity is a glioma stem cell (GSC) subpopulation. In this chapter, we review, highlight, and discuss controversies and clinical relevance of glioblastoma heterogeneity and its cellular basis. Characterization of how cancer stem cells (CSCs) behave is important in understanding how tumors are initiated and how they recur following initial treatment.
胶质母细胞瘤是一种预后不良的脑原发性肿瘤。病理检查表明,这种疾病的特点是肿瘤内形态异质性,而大量正在进行的基因组分析揭示了多层次的异质性。肿瘤内和患者间的异质性是由细胞、遗传和分子异质性支撑的,这被认为是肿瘤复发时间和对治疗耐药的关键决定因素。被认为有助于肿瘤异质性的建立和持续演变的关键细胞类型是神经胶质瘤干细胞(GSC)亚群。在这一章中,我们回顾、强调和讨论了胶质母细胞瘤异质性及其细胞基础的争议和临床相关性。阐明癌症干细胞(CSC)的行为特征对于理解肿瘤的发生以及初始治疗后肿瘤如何复发非常重要。